Cargando…

A multicenter analysis of genomic profiles and PD-L1 expression of primary lymphoepithelioma-like carcinoma of the lung

To understand the molecular mechanism of tumorigenesis of pulmonary lymphoepithelioma-like carcinoma and explore potential therapeutic strategies, we investigated the genomic profiles and PD-L1 expression of 29 Chinese pulmonary lymphoepithelioma-like carcinoma patients at various stages. We perform...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Zhanhong, Liu, Laiyu, Lin, Xinqing, Xie, Xiaohong, Gu, Yingying, Liu, Ming, Zhang, Jiexia, Ouyang, Ming, Lizaso, Analyn, Zhang, Hua, Feng, Weineng, Li, Bing, Han-Zhang, Han, Chen, Shuyin, Li, Shiyue, Zhong, Nanshan, Liu, Hao, Zhou, Chengzhi, Qin, Yinyin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113185/ https://www.ncbi.nlm.nih.gov/pubmed/31659278 http://dx.doi.org/10.1038/s41379-019-0391-9

Ejemplares similares

The clinical analysis of pulmonary lymphoepithelioma-like carcinoma with epithelioid granuloma
por: Gao, Guoying, et al.
Publicado: (2020)

A first case report of clinical response to targeted therapy in a patient with primary myoepithelial carcinoma of the lung harboring EGFR exon 19 deletion
por: Xie, Xiaohong, et al.
Publicado: (2020)

Unexpected favorable outcome to etoposide and cisplatin in a small cell lung cancer transformed patient: a case report
por: Xie, Zhanhong, et al.
Publicado: (2019)

Extracranial abscopal effect induced by combining immunotherapy with brain radiotherapy in a patient with lung adenocarcinoma: A case report and literature review
por: Lin, Xinqing, et al.
Publicado: (2019)

Case Report: Fatal Multiorgan Failure and Heterochronous Pneumonitis Following Pembrolizumab Treatment in a Patient With Large-Cell Neuroendocrine Carcinoma of Lung
por: Xie, Xiaohong, et al.
Publicado: (2021)

Treatment response and safety of immunotherapy for advanced non-small cell lung cancer with comorbid chronic obstructive pulmonary disease: a retrospective cohort study
por: Zhang, Kening, et al.
Publicado: (2022)

Evaluation of Cell Surface Vimentin Positive Circulating Tumor Cells as a Diagnostic Biomarker for Lung Cancer
por: Xie, Xiaohong, et al.
Publicado: (2021)

Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma
por: Lin, Xinqing, et al.
Publicado: (2020)

Successful therapy with bevacizumab combined with corticosteroids for crizotinib-induced interstitial lung disease
por: Xie, Xiaohong, et al.
Publicado: (2019)

Tumor immune microenvironment and mutational analysis of tracheal adenoid cystic carcinoma
por: Wang, Fei, et al.
Publicado: (2020)

Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study
por: Xie, Xiaohong, et al.
Publicado: (2022)

Clinical types of checkpoint inhibitor-related pneumonitis in lung cancer patients: a multicenter experience
por: Lin, Xinqing, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors Plus Single-Agent Chemotherapy for Advanced Non-Small-Cell Lung Cancer After Resistance to EGFR-TKI
por: Deng, Haiyi, et al.
Publicado: (2021)

Case Report: A Rare Case of Metachronous Multiple Primary Lung Cancers in a Patient With Successful Management by Switching From Anti-PD-1 Therapy to Anti-PD-L1 Therapy
por: Lin, Xinqing, et al.
Publicado: (2021)

Peripheral Blood Biomarkers for Early Diagnosis, Severity, and Prognosis of Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer
por: Lin, Xinqing, et al.
Publicado: (2021)

Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis
por: Lin, Xinqing, et al.
Publicado: (2022)

miR-802 inhibits the aggressive behaviors of non-small cell lung cancer cells by directly targeting FGFR1
por: Zhang, Jiexia, et al.
Publicado: (2022)

Management and Prognosis of Interstitial Lung Disease With Lung Cancer (ILD-LC): A Real-World Cohort From Three Medical Centers in China
por: Xiaohong, Xie, et al.
Publicado: (2021)

Safety and efficacy of immunotherapy rechallenge following checkpoint inhibitor-related pneumonitis in advanced lung cancer patients: a retrospective multi-center cohort study
por: Lin, Xinqing, et al.
Publicado: (2022)

The Treatment Status of Patients in NSCLC With RET Fusion Under the Prelude of Selective RET-TKI Application in China: A Multicenter Retrospective Research
por: Meng, Yan, et al.
Publicado: (2022)

Randomized phase III study comparing the first-line chemotherapy regimens in patients with driver mutation-negative advanced non-small cell lung cancer and poor performance status complicated with chronic obstructive pulmonary disease
por: Gao, Guoying, et al.
Publicado: (2021)

Identification and validation of a ferroptosis-related prognostic risk-scoring model and key genes in small cell lung cancer
por: Li, Suyang, et al.
Publicado: (2022)

PD-L1 expression in pulmonary lymphoepithelioma-like carcinoma: is it a prognostic biomarker?
por: Li, Wen, et al.
Publicado: (2022)

A retrospective real‐world experience of immunotherapy in patients with extensive stage small‐cell lung cancer
por: Qiu, Guihuan, et al.
Publicado: (2023)

Pulmonary Lymphoepithelioma-Like Carcinoma: A Mini-Review
por: Hu, Yan, et al.
Publicado: (2020)

Unsuspected Pneumocystis pneumonia in an HIV-seronegative patient with untreated lung cancer: circa case report
por: Chuang, Cai, et al.
Publicado: (2007)

Rechallenge with erlotinib in osimertinib-resistant lung adenocarcinoma mediated by driver gene loss: a case report
por: Liu, Lingli, et al.
Publicado: (2020)

Case report: Spontaneous remission in lung carcinoma with a late relapse after adjuvant immunotherapy: Exceptional tumor micro-environment
por: Chen, Yan, et al.
Publicado: (2023)

Heterogeneous constitutional mismatch repair deficiency with MSH6 missense mutation clinically benefits from pembrolizumab and regorafenib combination therapy: a case report and literature review
por: Xie, Tong, et al.
Publicado: (2021)

Lymphoepithelioma-like carcinoma of the upper urinary tract: A systematic review of case reports
por: Lai, Shi-Cong, et al.
Publicado: (2020)

Differences in the clinicopathological characteristics of pure and mixed invasive micropapillary breast carcinomas from eastern China
por: Wang, Rong, et al.
Publicado: (2021)

Malignant pleural effusion supernatant is an alternative liquid biopsy specimen for comprehensive mutational profiling
por: Guo, Zhihua, et al.
Publicado: (2019)

Comprehensive genomic profiling and PD-L1 expression of primary lymphoepithelioma-like carcinoma of the stomach and parotid gland
por: Cui, Qian, et al.
Publicado: (2022)

Proposed clinical phases for the improvement of personalized treatment of checkpoint inhibitor–related pneumonitis
por: Zhou, Chengzhi, et al.
Publicado: (2022)

Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study
por: Zhang, Yongchang, et al.
Publicado: (2021)

Lymphoepithelioma-like Carcinoma of the Urinary Bladder
por: Yun, Han Ki, et al.
Publicado: (2010)

PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma
por: Zhong, Yu-Min, et al.
Publicado: (2022)

Case Report: Primary lymphoepithelioma-like intrahepatic cholangiocarcinoma
por: Liu, Fei, et al.
Publicado: (2023)

A computed tomography-based preoperative risk scoring system to distinguish lymphoepithelioma-like gastric carcinoma from non-lymphoepithelioma-like gastric carcinoma
por: Li, Liming, et al.
Publicado: (2022)

Comprehensive characterization reveals sputum supernatant as a valuable alternative liquid biopsy for genome profiling in advanced non-small cell lung cancer
por: Xie, Xiaohong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_20kh8jckfm6egj9dii5d52s6ge